Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.

[1]  P. Campbell,et al.  Life histories of myeloproliferative neoplasms inferred from phylogenies , 2022, Nature.

[2]  R. Levine,et al.  A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN. , 2020, Blood advances.

[3]  O. Odenike,et al.  Genomics of MPN progression. , 2020, Hematology. American Society of Hematology. Education Program.

[4]  V. Ugo,et al.  Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. , 2020, Blood advances.

[5]  V. Najfeld,et al.  Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms , 2020, Acta Haematologica.

[6]  M. Voso,et al.  Treatment of Philadelphia‐negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors , 2019, Hematological oncology.

[7]  U. Gianelli,et al.  Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options , 2019, International journal of molecular sciences.

[8]  M. Giovannini,et al.  Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm , 2018, Acta Haematologica.

[9]  R. Hoffman,et al.  Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. , 2018, Leukemia research.

[10]  A. Bagg,et al.  JAK2 V617F‐positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group , 2018, British journal of haematology.

[11]  S. Langabeer,et al.  Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia , 2018, Case reports in hematology.

[12]  R. Houot,et al.  Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase , 2018, Leukemia & lymphoma.

[13]  D. Birnbaum,et al.  Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms , 2018, American journal of hematology.

[14]  A. Tefferi,et al.  Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. , 2018, Blood advances.

[15]  P. Guglielmelli,et al.  Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts , 2018, Leukemia.

[16]  M. Giovannini,et al.  Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation , 2017, Acta oncologica.

[17]  C. Récher,et al.  Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia , 2017, Oncotarget.

[18]  E. Raffoux,et al.  Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone , 2017, Leukemia & lymphoma.

[19]  H. Kantarjian,et al.  Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. , 2015, Leukemia research.

[20]  M. Voso,et al.  Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. , 2015, Leukemia research.

[21]  V. Bhatt.  Leukemic transformation in essential thrombocythemia. , 2014, Future oncology.

[22]  S. Armstrong,et al.  Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms , 2014, Proceedings of the National Academy of Sciences.

[23]  M. Minden,et al.  Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. , 2013, Blood.

[24]  B. Quesnel,et al.  Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). , 2010, Blood.

[25]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[26]  P. Guglielmelli,et al.  Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. , 2007, Blood.

[27]  H. Byun,et al.  Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition , 2007, British journal of haematology.